Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration.
Adaptive immunity
COVID-19
Immunology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
23 08 2021
23 08 2021
Historique:
received:
12
04
2021
accepted:
01
07
2021
pubmed:
9
7
2021
medline:
1
9
2021
entrez:
8
7
2021
Statut:
epublish
Résumé
Some studies suggest that recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 symptom duration. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (βCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher βCoV antibody titers were more likely recently infected with common βCoVs compared with individuals with lower antibody titers. Therefore, our data suggest that recent βCoV infections potentially limit the duration of symptoms following SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common βCoV infections transiently reduce symptom duration following SARS-CoV-2 infections.
Identifiants
pubmed: 34237028
pii: e150449
doi: 10.1172/jci.insight.150449
pmc: PMC8410018
doi:
pii:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007324
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001878
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069534
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055400
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32997649
Sci Immunol. 2020 Jul 29;5(49):
pubmed: 32727884
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Rev Immunol. 2020 Nov;20(11):709-713
pubmed: 33024281
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236